Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma

• Published in: Biochemical pharmacology Vol. 214; p. 115639
• Main Authors: Knapp, Kristen, Verchio, Vincent, Coburn-Flynn, Olivia, Li, Yahui, Xiong, Zhaohui, Morrison, Jamin C., Shersher, David D., Spitz, Francis, Chen, Xiaoxin
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01-08-2023
• Subjects: Carcinogenesis; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - prevention & control; Cell Competition; Esophageal Neoplasms - genetics; Esophageal Neoplasms - prevention & control; Esophageal Squamous Cell Carcinoma - prevention & control; Humans; 4NQO; KO; NRF2/NFE2L2; HNSCC; KEAP1; Norm; COX; Mut; WT; ESCC
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2023.115639

[Display omitted]
Esophageal squamous cell carcinoma (ESCC) is characterized by the development of cancer in the esophageal squamous epithelium through a step-by-step accumulation of genetic, epigenetic, and histopathological alterations. Recent studies have demonstrated that cancer-associated gene mutations exist in histologically normal or precancerous clones of the human esophageal epithelium. However, only a small proportion of such mutant clones will develop ESCC, and most ESCC patients develop only one cancer. This suggests that most of these mutant clones are kept in a histologically normal state by neighboring cells with higher competitive fitness. When some of the mutant cells evade cell competition, they become “super-competitors” and develop into clinical cancer. It is known that human ESCC is composed of a heterogeneous population of cancer cells that interact with and influence their environment and neighbors. During cancer therapy, these cancer cells not only respond to therapeutic agents but also compete with each other. Therefore, competition between ESCC cells within the same ESCC tumor is a constantly dynamic process. However, it remains challenging to fine-tune the competitive fitness of various clones for therapeutic benefits. In this review, we will explore the role of cell competition in carcinogenesis, cancer prevention, and therapy, using NRF2, NOTCH pathway, and TP53 as examples. We believe that cell competition is a research area with promising targets for clinical translation. Manipulating cell competition may help improve the prevention and therapy of ESCC.